New drug combo shows promise against advanced kidney cancer
NCT ID NCT03172754
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The goal is to find the safest dose and see how well the drugs shrink tumors. About 98 participants will take part, including those who have had prior treatment and those who have not.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cornell
New York, New York, 10021, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Johns Hopkins
Baltimore, Maryland, 21231, United States
-
US Oncology and Hematology
Albany, New York, 12206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?